Earnings / Specialty pharma
Scienture preliminary third-quarter revenue rises 256% sequentially as Arbli volume grows and REZENOPY ships
Preliminary, unaudited revenue of $1.22 million, up 256% from roughly $344,000 in the second quarter, as Arbli wholesale unit sales rose 74% sequentially and the August REZENOPY launch added initial shipments. Nasdaq restored compliance.